Basic Information
| LncRNA/CircRNA Name | H19 |
| Synonyms | H19, ASM, ASM1, BWS, D11S813E, LINC00008, NCRNA00008, WT2 |
| Region | GRCh38_11:1995176-2001470 |
| Ensemble | ENSG00000130600 |
| Refseq | NR_002196 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | cervical cancer |
| ICD-0-3 | C53 |
| Methods | qPCR, Luciferase Reporter Assay, Western blot. |
| Sample | cervical cancer tissues |
| Expression Pattern | down-regulated |
| Function Description | Function assays showed that overexpression of miR-138-5p reduced cervical cancer cell proliferation, arrested cells in the G0 /G1 phase, and induced cell apoptosis in vitro. Remarkably, SIRT1 was confirmed as a direct target of miR-138-5p in cervical cancer, and miR-138-5p exerted the reduced tumor functions by suppressing SIRT1 expression. Moreover, we further identified that lncRNA H19 could act as a molecular sponge of miR-138-5p in cervical cancer progression. Taken together, these results suggested that miR-138-5p could suppress cervical cancer cell progression by targeting SIRT1.This decreased expression of miR-138-5p correlated with advanced International Federation of Gynecology and Obstetrics (FIGO) stage, poor differentiation, lymph nodes metastasis, and poor overall survival of cervical cancer patients. |
| Pubmed ID | 28797320 |
| Year | 2017 |
| Title | Decreased Expression of MiR-138-5p by LncRNA H19 in Cervical Cancer Promotes Tumor Proliferation. |
External Links
| Links for H19 | GenBank HGNC NONCODE |
| Links for cervical cancer | OMIM COSMIC |